Notably, we observed co‐localization of HLA‐DR+ tumor cells with exhausted CD8+ T‐cell subsets, along with upregulation of immune checkpoint ligands such as PD‐L1, and a clear link to adverse clinical outcomes. The gene discussed is CD8A; the disease is neoplasm.